412 related articles for article (PubMed ID: 36344672)
1. Targeting HER2-positive breast cancer: advances and future directions.
Swain SM; Shastry M; Hamilton E
Nat Rev Drug Discov; 2023 Feb; 22(2):101-126. PubMed ID: 36344672
[TBL] [Abstract][Full Text] [Related]
2. HER2-directed therapy: current treatment options for HER2-positive breast cancer.
Ahmed S; Sami A; Xiang J
Breast Cancer; 2015 Mar; 22(2):101-16. PubMed ID: 25634227
[TBL] [Abstract][Full Text] [Related]
3. The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer.
von Arx C; De Placido P; Caltavituro A; Di Rienzo R; Buonaiuto R; De Laurentiis M; Arpino G; Puglisi F; Giuliano M; Del Mastro L
Cancer Treat Rev; 2023 Feb; 113():102500. PubMed ID: 36587473
[TBL] [Abstract][Full Text] [Related]
4. Clinical perspective: Antibody-drug conjugates for the treatment of HER2-positive breast cancer.
Najminejad Z; Dehghani F; Mirzaei Y; Mer AH; Saghi SA; Abdolvahab MH; Bagheri N; Meyfour A; Jafari A; Jahandideh S; Gharibi T; Amirkhani Z; Delam H; Mashatan N; Shahsavarani H; Abdollahpour-Alitappeh M
Mol Ther; 2023 Jul; 31(7):1874-1903. PubMed ID: 36950736
[TBL] [Abstract][Full Text] [Related]
5. Advances and future directions in the targeting of HER2-positive breast cancer: implications for the future.
Subbiah IM; Gonzalez-Angulo AM
Curr Treat Options Oncol; 2014 Mar; 15(1):41-54. PubMed ID: 24323591
[TBL] [Abstract][Full Text] [Related]
6. HER2 targeted therapy in breast cancer...beyond Herceptin.
Pal SK; Pegram M
Rev Endocr Metab Disord; 2007 Sep; 8(3):269-77. PubMed ID: 17899385
[TBL] [Abstract][Full Text] [Related]
7. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer.
Spector NL; Blackwell KL
J Clin Oncol; 2009 Dec; 27(34):5838-47. PubMed ID: 19884552
[TBL] [Abstract][Full Text] [Related]
8. Margetuximab and trastuzumab deruxtecan: New generation of anti-HER2 immunotherapeutic agents for breast cancer.
Nur Husna SM; Wong KK
Mol Immunol; 2022 Dec; 152():45-54. PubMed ID: 36272249
[TBL] [Abstract][Full Text] [Related]
9. An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance.
Mitra D; Brumlik MJ; Okamgba SU; Zhu Y; Duplessis TT; Parvani JG; Lesko SM; Brogi E; Jones FE
Mol Cancer Ther; 2009 Aug; 8(8):2152-62. PubMed ID: 19671734
[TBL] [Abstract][Full Text] [Related]
10. Optimizing outcomes in HER2-positive breast cancer: the molecular rationale.
Esteva FJ; Pusztai L
Oncology (Williston Park); 2005 Nov; 19(13 Suppl 5):5-16. PubMed ID: 19364051
[TBL] [Abstract][Full Text] [Related]
11. Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985).
Xu Z; Guo D; Jiang Z; Tong R; Jiang P; Bai L; Chen L; Zhu Y; Guo C; Shi J; Yu D
Eur J Med Chem; 2019 Dec; 183():111682. PubMed ID: 31563805
[TBL] [Abstract][Full Text] [Related]
12. HER2 therapy: molecular mechanisms of trastuzumab resistance.
Nahta R; Esteva FJ
Breast Cancer Res; 2006; 8(6):215. PubMed ID: 17096862
[TBL] [Abstract][Full Text] [Related]
13. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
Nahta R; O'Regan RM
Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer.
Nahta R; Yu D; Hung MC; Hortobagyi GN; Esteva FJ
Nat Clin Pract Oncol; 2006 May; 3(5):269-80. PubMed ID: 16683005
[TBL] [Abstract][Full Text] [Related]
15. Recent Updates on the Therapeutic Potential of HER2 Tyrosine Kinase Inhibitors for the Treatment of Breast Cancer.
Singla H; Munshi A; Banipal RPS; Kumar V
Curr Cancer Drug Targets; 2018; 18(4):306-327. PubMed ID: 28669349
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of action of anti-HER2 monoclonal antibodies.
Baselga J; Albanell J
Ann Oncol; 2001; 12 Suppl 1():S35-41. PubMed ID: 11521720
[TBL] [Abstract][Full Text] [Related]
17. Emerging drugs targeting human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer.
Awada G; Gombos A; Aftimos P; Awada A
Expert Opin Emerg Drugs; 2016; 21(1):91-101. PubMed ID: 26817602
[TBL] [Abstract][Full Text] [Related]
18. Evolving novel anti-HER2 strategies.
Jones KL; Buzdar AU
Lancet Oncol; 2009 Dec; 10(12):1179-87. PubMed ID: 19959074
[TBL] [Abstract][Full Text] [Related]
19. Sortilin-related receptor is a druggable therapeutic target in breast cancer.
Al-Akhrass H; Pietilä M; Lilja J; Vesilahti EM; Anttila JM; Haikala HM; Munne PM; Klefström J; Peuhu E; Ivaska J
Mol Oncol; 2022 Jan; 16(1):116-129. PubMed ID: 34564954
[TBL] [Abstract][Full Text] [Related]
20. A Cancer-Specific Monoclonal Antibody against HER2 Exerts Antitumor Activities in Human Breast Cancer Xenograft Models.
Kaneko MK; Suzuki H; Ohishi T; Nakamura T; Tanaka T; Kato Y
Int J Mol Sci; 2024 Feb; 25(3):. PubMed ID: 38339219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
